ImmunityBio, Inc.（纳斯达克代码：IBRX）今日盘中大涨29.50%，创下近期新高。
消息面上，公司公布了多款癌症疗法的积极临床试验数据。其中，针对一线BCG初治非肌层浸润性膀胱癌的Anktiva®与BCG联合疗法中期分析结果积极，患者入组人数超出预期。此外，其非化疗CD19靶向CAR-NK细胞疗法在华氏巨球蛋白血症患者中实现了持续15个月的持久性完全缓解，标志着血液肿瘤治疗领域的重大突破。公司还公布了罕见血癌疗法的积极数据，进一步提振了投资者信心。
这些突破性成果不仅展现了ImmunityBio在癌症治疗领域的创新能力，也为后续监管审批和商业化奠定了坚实基础。市场普遍认为，这些进展将显著提升公司的长期增长潜力。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.